ArticleScientific reports2026
A deep learning ensemble framework for multi-subtype renal tumor classification using contrast-enhanced CT.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence in the radiologic diagnosis of major urological cancers: a meta-analysis.World journal of urology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is considered the most aggressive and common form of renal cancer. Therefore, early detection is crucial to ensure appropriate and effective treatment planning. In our study, we propose a novel computer-aided diagnostic (CAD) approach which incorporates a deep learning ensemble to differentiate between five renal tumor subtypes, utilising the modality of contrast-enhanced computed tomography (CE-CT). The addressed renal lesions are malignant tumors (chromophobe RCC (chRCC), papillary RCC (pRCC), and clear cell RCC (ccRCC)) and benign tumors (renal oncocytoma (RO) and angiomyolipoma (AML)). Our study includes 280 patients who underwent renal biopsy, 112 patients were diagnosed with benign tumors and 168 patients were diagnosed with malignant tumors. Specifically, we propose a multi-stage classification pipeline to categorize the five types of renal tumors, and at each stage, we use a novel ensemble system that is composed of three components: (i) taking the average probability of the output of a convolutional neural network (CNN) resulting from multiple images per patient; (ii) applying a long-short term memory (LSTM) followed by a feed-forward neural network on the last dense layer of the CNN; (iii) applying a 1D convolutional encoder succeeded by a feed-forward neural network on the last dense layer of the CNN. Our proposed approach outperformed previous studies in discriminating between benign and malignant tumors, and to the best of our knowledge, our study is the first paper to account for the five mentioned renal tumor subtypes. Our classification accuracies were 96.4%, 100%, 91.2%, 93.8% for the discrimination between benign vs. malignant, AML vs. RO, ccRCC vs. non-ccRCC, and pRCC vs. chRCC, respectively. Our proposed CAD and the obtained results establish the potential of a reliable non-invasive diagnostic utility for renal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.